Shi R - Search Results

1

Population Pharmacokinetics of Patritumab Deruxtecan in Patients With Solid Tumors.

Lu Y, Shimizu S, Sawamura R, Tajima N, He L, Lee M, Abutarif M, Shi R. Lu Y, et al. Among authors: shi r. J Clin Pharmacol. 2023 Jan;63(1):77-90. doi: 10.1002/jcph.2137. Epub 2022 Sep 17. J Clin Pharmacol. 2023. PMID: 36053771 Free PMC article.

2

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer.

Jänne PA, Baik C, Su WC, Johnson ML, Hayashi H, Nishio M, Kim DW, Koczywas M, Gold KA, Steuer CE, Murakami H, Yang JC, Kim SW, Vigliotti M, Shi R, Qi Z, Qiu Y, Zhao L, Sternberg D, Yu C, Yu HA. Jänne PA, et al. Among authors: shi r. Cancer Discov. 2022 Jan;12(1):74-89. doi: 10.1158/2159-8290.CD-21-0715. Epub 2021 Sep 21. Cancer Discov. 2022. PMID: 34548309 Free PMC article. Clinical Trial.

3

Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Shi R, Lu T, Ku G, Ding H, Saito T, Gibiansky L, Agarwal P, Li X, Jin JY, Girish S, Miles D, Li C, Lu D. Shi R, et al. Cancer Chemother Pharmacol. 2020 Sep;86(3):347-359. doi: 10.1007/s00280-020-04119-8. Epub 2020 Aug 8. Cancer Chemother Pharmacol. 2020. PMID: 32770353 Free PMC article. Clinical Trial.

4

Fixed dosing versus body size-based dosing of therapeutic peptides and proteins in adults.

Zhang S, Shi R, Li C, Parivar K, Wang DD. Zhang S, et al. Among authors: shi r. J Clin Pharmacol. 2012 Jan;52(1):18-28. doi: 10.1177/0091270010388648. Epub 2011 Jan 13. J Clin Pharmacol. 2012. PMID: 21233304

5

Integrated Two-Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non-Hodgkin Lymphoma.

Lu D, Lu T, Gibiansky L, Li X, Li C, Agarwal P, Shemesh CS, Shi R, Dere RC, Hirata J, Miles D, Chanu P, Girish S, Jin JY. Lu D, et al. Among authors: shi r. CPT Pharmacometrics Syst Pharmacol. 2020 Jan;9(1):48-59. doi: 10.1002/psp4.12482. Epub 2019 Dec 23. CPT Pharmacometrics Syst Pharmacol. 2020. PMID: 31749251 Free PMC article.

6

Physiologically Based Pharmacokinetic Model-Informed Drug Development for Polatuzumab Vedotin: Label for Drug-Drug Interactions Without Dedicated Clinical Trials.

Samineni D, Ding H, Ma F, Shi R, Lu D, Miles D, Mao J, Li C, Jin J, Wright M, Girish S, Chen Y. Samineni D, et al. Among authors: shi r. J Clin Pharmacol. 2020 Oct;60 Suppl 1:S120-S131. doi: 10.1002/jcph.1718. J Clin Pharmacol. 2020. PMID: 33205435

7

Comparable drug levels and immunogenicity in patients with axial spondyloarthritis treated with adalimumab originator and biosimilar: A retrospective study from two centers of China.

Fu ZC, Cheng XG, Zhang GW, Shi RG, Zhang LJ, Sun HT, Huang JX. Fu ZC, et al. Among authors: shi rg. Int J Rheum Dis. 2024 May;27(5):e15190. doi: 10.1111/1756-185X.15190. Int J Rheum Dis. 2024. PMID: 38736279 No abstract available.

8

Enhancing renewable energy certificate transactions through reinforcement learning and smart contracts integration.

He Q, Wang J, Shi R, He Y, Wu M. He Q, et al. Among authors: shi r. Sci Rep. 2024 May 12;14(1):10838. doi: 10.1038/s41598-024-60527-3. Sci Rep. 2024. PMID: 38735996 Free PMC article.

9

Neuropathy target esterase activity defines phenotypes among PNPLA6 disorders.

Liu J, He Y, Lwin C, Han M, Guan B, Naik A, Bender C, Moore N, Huryn LA, Sergeev YV, Qian H, Zeng Y, Dong L, Liu P, Lei J, Haugen CJ, Prasov L, Shi R, Dollfus H, Aristodemou P, Laich Y, Németh AH, Taylor J, Downes S, Krawczynski MR, Meunier I, Strassberg M, Tenney J, Gao J, Shear MA, Moore AT, Duncan JL, Menendez B, Hull S, Vincent AL, Siskind CE, Traboulsi EI, Blackstone C, Sisk RA, Miraldi Utz V, Webster AR, Michaelides M, Arno G, Synofzik M, Hufnagel RB. Liu J, et al. Among authors: shi r. Brain. 2024 May 13:awae055. doi: 10.1093/brain/awae055. Online ahead of print. Brain. 2024. PMID: 38735647

10

Targeting STAT3 potentiates CDK4/6 inhibitors therapy in head and neck squamous cell carcinoma.

Dong L, Liu C, Sun H, Wang M, Sun M, Zheng J, Yu X, Shi R, Wang B, Zhou Q, Chen Z, Xing B, Wang Y, Yao X, Mei M, Ren Y, Zhou X. Dong L, et al. Among authors: shi r. Cancer Lett. 2024 May 10:216956. doi: 10.1016/j.canlet.2024.216956. Online ahead of print. Cancer Lett. 2024. PMID: 38735381

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,434 results

Search Page